Polyrizon Ltd.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| PLRZ | PYPD | IBO | PHRM.CN | PLRX | AIM | |
|---|---|---|---|---|---|---|
| Market cap | 27.02M | 118.21M | 35.42M | 4.55M | 52.75M | 6.42M |
| P/E (TTM) | — | — | 0.4 | — | — | — |
| Forward P/E | — | -5.6 | — | -0.5 | -0.7 | -0.4 |
| Price/book | 1.0 | 22.0 | 3.3 | 7.1 | 0.4 | 0.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +96.37% | +44.06% | −39.34% | −52.38% | −47.50% | −90.12% |
| Today | −2.46% | +6.59% | +1.99% | −16.67% | −1.03% | +0.19% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All PLRZ news ›Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker
The U.S clinical study is designed to evaluate the efficacy, safety and tolerability of the NASARIX (PL-14) Allergy Blocker in patients with seasonal allergic rhinitis The enrollment of the first patient represents a significant milestone…
Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement
RAANANA, ISRAEL, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a development-stage biotech company special... Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private…
Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform
A new patent application covers Polyrizon’s proprietary mucoadhesive platform and its potential applications in nasal drug delivery. The divisional application, titled “Mucoadhesive Polymers for Nasal Drug Delivery,” was assigned U.S.…
Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker
All 120 planned participants randomized across five clinical sites in the United StatesRaanana, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Polyr... Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com5
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 5 articles, not a forecast.